Bioceres Crop Solutions Corp.

Hello, everyone. Thank you for joining us and welcome to Bioceres Crop Solutions Fiscal Third Quarter 2026 Financial and Operational Results Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star and the number one to raise your hand. To withdraw your question, press star one again. I will now hand the call conference over to Paola Savanti, Head of Investor Relations. Paola, please go ahead.

Thank you and good morning, everyone. Welcome to Bioceres Crop Solutions Third Fiscal Quarter 2026 Earnings Conference Call. Our prepared remarks today will be led by our Chief Executive Officer Federico Trucco, our General Counsel, José Roque, and our Chief Financial Officer, Ezequiel Zimmermacher. All of them will be available for the Q&A session following the presentation. During this call, we will be making forward-looking statements. These statements are based on current expectations and assumptions that are subject to various risks and uncertainties. I refer you to the forward-looking statement section of the earnings release and presentation, as well as the recent filings with SEC. Thank you. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. In today's presentation, we will be making references to certain non-GAAP financial measures. Reconciliations of the non-GAAP measures can be found in our earnings press release. This conference call is being webcast and the link is available at our investor relations website. It is now my pleasure to turn the call over to Federico.

Thanks, Paula, and good morning to everyone. Thanks for joining us today. Please turn to slide number three for today's key business and financial highlights. This quarter reflects a period of transition and operational refocusing for the company, while it is historically our weakest quarter from a baseline business perspective. Total revenues and gross profits showed a decline compared to the same quarter last year, which was partially offset by an improvement in operational expenses. Net loss was $10 million, primarily reflecting lower gross profit as well as increased financial expenses, all of which will be described in greater detail later in the presentation. Also, in the last three years, we have put profits from IP rights and other commercial arrangements in this quarter, which help us offset baseline operating losses. Although we continue to explore strategic arrangements with our partners on a regular basis and see these as a recurrent source of profitability, this year, the timing of profit generating arrangements did not coincide with initial months of the calendar year. As I have stated in my message to shareholders of March 16th, we recognize the significance of the events surrounding ProPharm and the uncertainty generated by the ongoing litigation process. José Roque, our General Counsel, will now provide an update of the ongoing litigation. Please turn to slide number four.